# CooperCompanies account plan

> CooperCompanies is a medical device group in contact lenses (CooperVision) and fertility and women's health (CooperSurgical); FY2025 net sales $4,092.4 million.

## At a glance

The Cooper Companies (Nasdaq: COO), headquartered in San Ramon, California, is a global medical device company selling in over 130 countries through two segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health). In FY2025 (year to October 31, 2025) net sales were $4,092.4 million, net income $374.9 million and operating income $682.9 million. It has a workforce of more than 15,000, 52% in the Americas and 42% in EMEA. On October 27, 2026 Al White stepped down as CEO; Executive Chair Walt Rosebrough oversees day-to-day operations until a permanent CEO is appointed.

## Business units

- **CooperVision** ($2,743.8 million FY2025 net sales (about 67% of group, computed)): Develops, manufactures and markets soft contact lenses, including Biofinity, MyDay, clariti and the MiSight 1 day myopia-management lens, sold through eye care practitioners, optical chains, retailers and distributors. FY2025 sales rose 5% with operating income of $729.6 million; Q3 FY2026 sales were flat at $717.0 million as Cooper cut U.S. channel inventory. Led by Gerard H. Warner III.
- **CooperSurgical** ($1,348.6 million FY2025 net sales (about 33% of group, computed)): Fertility products and services (IVF media, lab equipment, donor gametes, genetic testing) and office and surgical products including the Paragard copper IUD, sold to OB/GYN offices, hospitals and fertility clinics. FY2025 sales rose 5% (office and surgical $824.0 million, fertility $524.6 million) but operating income fell 63%; the Board decided in September 2026 to keep the unit after a sale process. Led by Holly R. Sheffield.

## Strategic priorities

- **CooperVision organic growth first**: After the strategic review completed on September 9, 2026, investment in CooperVision commercial strengths, innovation and organic growth is the top priority; CooperSurgical prioritises organic growth and operational improvement.
- **Commercial execution**: Cooper is expanding CooperVision's global sales and marketing organisation; the U.S. sales force expansion will cover about 5,000 additional doors, with reps in the field around fiscal Q2 2027.
- **Faster innovation**: New product introductions are being accelerated, with The Vision Centre R&D hub opened on September 23, 2026; launches planned for around 2030 are being pulled forward.
- **Myopia management and premium dailies**: MiSight grew 20% organic in Q3 FY2026 and single-use silicone hydrogel franchises such as MyDay remain a focus.
- **Cash generation and buybacks**: A long-term free cash flow objective exceeding $2.2 billion for FY2026-FY2028, with the buyback authorization raised to $3.0 billion in September 2026.
- **New CEO and board refresh**: A CEO search is under way with Russell Reynolds, and the Board shrinks to seven nominees for 2027, four with extensive medical device experience.

## Latest results

In Q3 FY2026 (quarter to July 31, 2026) revenue was $1.066 billion, up 1% reported and organic, and non-GAAP EPS was $1.15 (+4%); GAAP EPS of $2.24 included a $307.2 million discrete UK tax benefit. CooperVision was flat at $717.0 million because of reductions in U.S. channel inventory, while CooperSurgical rose to $349.2 million (+3% organic). Free cash flow was a record $273.0 million. FY2026 guidance was cut to revenue of $4.229-4.252 billion and non-GAAP EPS of $4.51-4.55, and was reaffirmed on October 27, 2026.

## Investments and deals

- **Capital expenditure**: FY2025 capex was $362.4 million, of which CooperVision $322.9 million, including investment in distribution and packaging such as a new packaging facility in Puerto Rico.
- **R&D hub**: The Vision Centre, CooperVision's new global R&D innovation hub, opened on September 23, 2026.
- **Share repurchases**: 4.9 million shares bought for $339.1 million in Q3 FY2026 and $445 million in the fiscal year so far; authorization raised from $2 billion to $3 billion.
- **Inventory and logistics**: An AI-based inventory control system and a revised logistics approach to support future direct shipping capabilities.

## Challenges and risks

- **Commercial under-coverage**: The former CEO said Cooper has fewer salespeople in the field than its competitors and no product in the super premium daily lens segment.
- **U.S. channel destocking and Asia softness**: CooperVision Americas fell 2% in Q3 FY2026 on channel inventory reductions, and Asia Pacific fell 10% on softness in Japan and China.
- **Paragard competition**: A competing non-hormonal IUD has been approved, which the Board cited as a temporary factor behind its valuation disconnect.
- **Litigation and tax disputes**: The embryo culture media recall cost a $272.0 million net litigation charge, and a UK payroll tax dispute carries a possible loss of up to £71.7 million plus interest.
- **Leadership transition**: The new Executive Chair says recent performance has not met expectations while a permanent CEO is sought.

## What leadership says

> "The Company's recent performance has not met our expectations, and the Board believes decisive action is needed to ensure the Company reaches its long-term potential." — Walt Rosebrough, Executive Chair, Leadership transition press release, October 27, 2026

> "We don't have enough salespeople on the street. We have quite a bit less than our competitors have out there right now." — Al White, President and CEO (stepped down October 27, 2026), Q3 FY2026 earnings call, September 9, 2026

> "The process identified meaningful opportunities to enhance execution, sharpen our strategic focus and accelerate innovation." — Al White, President and CEO (stepped down October 27, 2026), Strategic review completion press release, September 9, 2026

> "Our fiduciary duty is to maximize shareholder value, and the Board is collectively aligned that given the offers received, retaining CooperSurgical is the best path forward to creating shareholder value at this time." — Colleen Jay, Chair, Strategic review completion press release, September 9, 2026


## Where a supplier can help

- **Sales force expansion**: The U.S. sales force expansion and the commercial execution priority create needs in recruiting, onboarding, territory planning and sales enablement.
- **AI targeting and analytics**: Cooper is investing in AI-driven targeting and analytics tools for its commercial teams, tied to the commercial execution priority.
- **Logistics and direct shipping**: The revised inventory and logistics approach and future direct shipping open opportunities for fulfilment, packaging and supply-chain software suppliers.
- **Operational efficiency**: Cost-reduction and efficiency programmes at both segments favour suppliers of automation and productivity tools.
- **R&D and manufacturing platform**: Accelerated product launches and The Vision Centre's standardized manufacturing platform need equipment, materials and engineering partners.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [The Cooper Companies, Inc. Annual Report on Form 10-K for the fiscal year ended October 31, 2025](https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm)

Annual report · 2025-12-05

- The Cooper Companies (CooperCompanies, Nasdaq: COO) is a global medical device group headquartered in San Ramon, California, selling in over 130 countries through two segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health).
- FY2025 (year to October 31, 2025) net sales were $4,092.4 million (FY2024: $3,895.4 million); net income $374.9 million (FY2024: $392.3 million); operating income $682.9 million, down 3%.
- CooperVision: $2,743.8 million net sales, up 5%, operating income $729.6 million (27% of sales); growth from Biofinity, MyDay and MiSight, while legacy hydrogel products declined. EMEA grew 8%, Americas 5%, Asia Pacific flat.
- CooperSurgical: $1,348.6 million net sales, up 5% (office and surgical $824.0 million, fertility $524.6 million), but operating income fell 63% to $43.4 million on inventory and long-lived asset write-offs, severance and amortization.
- Workforce optimization initiatives cost $35.0 million of termination benefits in FY2025; gross margin slipped to 66% from 67%.
- Capital allocation: share buyback authorization raised to $2.0 billion in September 2025; 4.1 million shares repurchased for $290.1 million in FY2025; no dividend since December 2023.
- Capex of $362.4 million (CooperVision $322.9 million); operating cash flow $796.1 million; debt facilities of $3,800.0 million with $2,456.3 million drawn, including a $1,500.0 million term loan maturing December 17, 2026.
- Workforce of more than 15,000 (52% Americas, 42% EMEA, 6% Asia Pacific); about 500 people in R&D; R&D spend $172.2 million.
- Key risks named: tariffs and trade barriers, inflation, FX, international operations (including China), acquisitions, pricing pressure, reimbursement, EU MDR/IVDR recertification, product recalls.

### [The Cooper Companies, Inc. Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (Q3 fiscal 2026)](https://www.sec.gov/Archives/edgar/data/711404/000162828026061160/coo-20260731.htm)

Interim report · 2026-09-09

- Q3 FY2026 (quarter to July 31, 2026): CooperVision sales $717.0 million (flat), CooperSurgical $349.2 million (+2%); nine-month CooperVision sales $2,135.6 million (+5%) and CooperSurgical $1,036.2 million (+4%).
- CooperVision Americas fell 2% in the quarter "due to reductions in U.S. channel inventory"; EMEA +6%; Asia Pacific -10% on softness in Japan and China; legacy hydrogel sales declined.
- Gross margin rose to 67% (Q3 FY2025: 65%) because FY2025 included inventory write-offs from a CooperSurgical product line exit; group operating income $222.0 million (+26%).
- A $272.0 million net litigation expense (embryo culture media recall of December 2023) pushed CooperSurgical to a nine-month operating loss of $157.1 million; $306.8 million was paid in August 2026 to settle substantially all claims.
- A $307.2 million discrete tax benefit was booked after HMRC closed its examination of the 2020 transfer of CooperVision IP to the UK.
- Headcount reductions lowered SGA at both segments; corporate costs rose on "strategic review costs".
- Buybacks: 4.9 million shares for $339.1 million in the quarter; authorization raised by $1.0 billion to $3.0 billion in September 2026.
- $950.0 million of term loans extended to February 3, 2031; a UK payroll tax dispute (Sauflon acquisition) carries a possible loss of up to £71.7 million plus interest.

### [CooperCompanies Announces Third Quarter 2026 Results (press release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/cooperq32026pressrelease.htm)

Interim report · 2026-09-09

- Q3 FY2026 revenue $1.066 billion, up 1% reported and 1% organic; GAAP diluted EPS $2.24 (prior year $0.49), lifted by a $307.2 million discrete UK tax benefit; non-GAAP EPS $1.15, up 4%.
- CooperVision revenue $717.0 million, flat organically; Americas -2%, EMEA +5% organic, Asia Pacific -5% organic.
- CooperSurgical revenue $349.2 million, up 3% organic; fertility $141.2 million (+5% organic), office and surgical $208.0 million (+2%).
- Free cash flow $273.0 million, up 66%; $339.1 million of stock repurchased; buyback authorization expanded from $2 billion to $3 billion.
- Guidance cut for CooperVision: FY2026 revenue $4.229-4.252 billion (organic +2% to +3%), CVI $2.828-2.842 billion (organic +1% to +2%), CSI $1.401-1.410 billion; FY2026 non-GAAP EPS $4.51-4.55.
- Q4 FY2026 guide: revenue $1.057-1.080 billion, CVI organic -2% to 0%, CSI organic +4% to +6%; free cash flow objective above $2.2 billion for FY2026-FY2028 reaffirmed.
- Al White: Cooper "proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4"; the strategic review was completed.

### [CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization (press release, Exhibit 99.2)](https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/cooperq32026pressreleaseex.htm)

Report · 2026-09-09

- CooperCompanies completed the strategic review it started in December 2025, covering portfolio, capital allocation, corporate structure, leadership, operations and strategy.
- The Board evaluated selling CooperSurgical with "numerous parties" and unanimously decided to keep it: offers received were not in shareholders' best interest.
- The Board blamed temporary factors: a competitive entrant in the non-hormonal IUD market (against Paragard) and the recent fertility litigation settlement.
- Share repurchase authorization expanded from $2 billion to $3 billion; $445 million of shares repurchased in the fiscal year so far.
- Top priority: investment in CooperVision "commercial strengths, innovation, and organic growth"; CooperSurgical to prioritize organic growth and operational improvement.
- Actions: expanding CooperVision's global sales and marketing organization, cost-reduction and efficiency programs, new inventory and logistics approach (future direct shipping), accelerated new product introductions and opening of The Vision Centre R&D hub on September 23, 2026.
- Two independent directors added during the review after shareholder engagement.

### [CooperCompanies Announces Leadership Transition and Board Refreshment (press release, Exhibit 99.1 to Form 8-K)](https://www.sec.gov/Archives/edgar/data/711404/000119312526434317/d141889dex991.htm)

Report · 2026-10-27

- On October 27, 2026 Al White stepped down as President and CEO and from the Board, effective immediately, after 20 years with the company; he stays as a strategic advisor through April 1, 2027.
- Independent director Walt Rosebrough (CEO of STERIS 2007-2021, former Hill-Rom CEO) was elected Executive Chair and takes direct oversight of day-to-day operations until a permanent CEO is appointed.
- CEO search under way with Russell Reynolds, overseen by a committee of Lawrence Kurzius, Cynthia Lucchese and Teresa Madden.
- Rosebrough: "The Company's recent performance has not met our expectations, and the Board believes decisive action is needed".
- Shlomi Nachman, former J&J Company Group Chairman whose portfolio included Vision, joins the Board on December 8, 2026; Barbara Carbone, Colleen Jay and Robert Weiss will not stand for re-election in 2027.
- The Board shrinks to seven nominees, four with extensive medical device experience.
- FY2026 guidance given on September 9, 2026 reaffirmed.

### [CooperCompanies Q3 fiscal 2026 earnings call transcript (September 9, 2026)](https://www.tradingkey.com/news/transcripts/262159666-tradingkey)

Executive talk · Albert G. White III, President and Chief Executive Officer (stepped down October 27, 2026) · 2026-09-09

- Al White and CFO Brian Andrews presented Q3 FY2026: revenue $1.066 billion (+1%), non-GAAP EPS $1.15 (+4%), record quarterly free cash flow of $273 million.
- CooperVision flat at $717 million because Cooper deliberately cut U.S. channel inventory; White says the Americas "would have reported growth around 5%" without it and U.S. consumption grows mid-single digits; a similar reduction is planned in Q4.
- White names commercial execution as the problem: "We don't have enough salespeople on the street"; a U.S. sales force expansion will cover "something like 5,000 additional doors", with reps in the field around early to mid fiscal Q2 2027.
- Strategic review ended with CooperSurgical retained; White on keeping both: "it's really the P&L", thanks to shared back-office services.
- Investment priority: CooperVision organic growth first ("100%, yes"), fertility second; R&D launches planned for around 2030 are being pulled forward a couple of years.
- Product momentum: MyDay double-digit, MiSight +20% organic, fertility +5% to $141 million; China remains weak and is "less than 2% of revenues".
- Gaps named: no products in the "super premium" daily lens segment; legacy hydrogel rationalization to finish in Q4; Paragard faces a new non-hormonal IUD competitor.
- Andrews: Q4 non-GAAP EPS $1.05-1.09; GILTI to lift the non-GAAP tax rate from roughly 15.5% to roughly 17.5% in fiscal 2027.

### [Cooper (COO) Q2 2026 earnings call transcript (June 4, 2026)](https://www.fool.com/earnings/call-transcripts/2026/06/05/cooper-coo-q2-2026-earnings-transcript/)

Executive talk · Albert G. White III, President and Chief Executive Officer (stepped down October 27, 2026) · 2026-06-05

- Q2 FY2026: record revenue of $1.08 billion (+8%, +5% organic) and non-GAAP EPS of $1.21 (+26%), the "tenth consecutive quarter of beating consensus earnings expectations".
- CooperVision $724 million: Americas +7%, EMEA +6%, Asia Pac -6% (legacy hydrogel rationalization plus weaker Japan and China); Cooper claims roughly 1/3 of all contact lens wearers and an 18th consecutive year of share gains in 2025.
- MiSight grew 24% to $32 million; Japan launch "exceeding expectations"; MyDay MiSight launched in Europe.
- CooperSurgical $358 million (+6% organic); fertility +10% organic to $144 million on capital equipment and Middle East restocking; normalizing to mid-single digits.
- Embryo culture media litigation: settlements with over 95% of claimants, net charge $271.6 million; strategic review then moved to "round 2" with multiple parties interested in the whole of CooperSurgical.
- White on the valuation: "I look at where our valuation is today, which I believe is absurd"; most sale proceeds would go to buybacks.
- FY2026 guidance at the time: revenue $4.28-4.32 billion; CooperVision organic +3.5% to 4.5%; EPS $4.58-4.66; free cash flow about $650 million excluding litigation.
- A new AI-based inventory control system cuts CooperVision inventory, pressuring gross margin but helping the $2.2 billion FY2026-2028 free cash flow goal.

## Questions about CooperCompanies

### What does CooperCompanies do?

It is a global medical device company with two segments: CooperVision, which makes contact lenses, and CooperSurgical, which serves fertility and women's health.

### What is CooperCompanies' revenue?

FY2025 net sales were $4,092.4 million. FY2026 guidance is $4.229-4.252 billion.

### How many employees does CooperCompanies have?

A workforce of more than 15,000, selling in over 130 countries.

### Who leads CooperCompanies?

Al White stepped down as CEO on October 27, 2026; Executive Chair Walt Rosebrough oversees day-to-day operations while a CEO search runs.

### Is CooperCompanies selling CooperSurgical?

No. The Board evaluated a sale with numerous parties and decided in September 2026 to keep CooperSurgical.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
